Switching patients with IBD from intravenous to subcutaneous biologics might improve convenience for patients but results in a financial loss to health services.
The findings have prompted the Melbourne gastroenterologists behind the economic analysis to call for alternative models of funding that reduce reliance on intravenous biologic-generated income in IBD care and incentivise a switch.
Their retrospective analysis involved 344 patients who received intravenous infliximab or vedolizumab in the outpatient infusion centre of a tertiary IBD centre between July 2019 and June 2021.
Of the cohort (55% male, median age 37 for infliximab and 45 for vedolizumab), just over half had Crohn’s disease (54%) and the rest had ulcerative colitis (46%).
Data were collated from patients’ electronic medical records, pharmacy dispensing systems and the hospital business intelligence unit, while the financial impact was estimated under two additional scenarios using a random 10% and 30% of the cohort.
This accounted for the fact that an entire cohort switch would not be representative of real practice, said the researchers from the Austin Hospital and the Austin Academic Centre at the University of Melbourne.
Findings published in Internal Medicine Journal [link here] suggested that transitioning patients from intravenous to subcutaneous administration would result in a total loss of $2,732,123.75 (AUD) over two years to the health service.